Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond
Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of today’s pressing global challenges. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is increasingly critical.
The inaugural EFIB Statement of October 2021 created a baseline for industrial biotechnology and bioeconomy vision in policy, regulatory and landscape development. The EuropaBio’s EFIB Vilnius Statement of 2022 evolves to address this long-term vision and ambition within the context of challenges and needs over the next 12 months.
We invite you to join us for a discussion on the role and potential of enabling technologies in the EU green transition, with a focus on priorities for the shorter term and building up to the longer term.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.